PDF
ePub
Citation
Print
Abstract
Purpose
We identified new thresholds for prostate-specific antigen velocity (PSAV) for screening of prostate cancer in Korean patients younger than 60 years old based on PSA serial data obtained from our hospital's health promotion center.
Materials and Methods
The study population was retrieved from 10,011 patients, 40 to 79 years old, with 2 or more PSA values within five years who visited our hospital's health promotion center between January 2002 and December 2006, including 100 patients with prostate cancer. These subjects were divided into 2 age groups, 40-59 years old and 60-79 years old, and their PSAV were calculated as the rate of PSA change using the first and last values only. A receiver operating characteristic (ROC) curve was used to analyze the performance of PSAV in the screening of prostate cancer, and we developed new PSAV thresholds by comparing sensitivity and specificity at different PSAV levels.
Results
Overall prostate cancer prevalence was 0.6% (45) in younger (40-59 years old) patients and 2.1% (55) in older (60 to 79 years old) patients. The median PSAV in the normal control group and the cancer group were 0.047ng/ml/year vs 0.877ng/ml/year in younger patients (p＜0.0001) and 0.067ng/ml/year vs 0.642ng/ml/year in older patients (p＜0.0001). For younger patients, the sensitivity and specificity were 55.6% and 99.2% at PSAV 0.75ng/ml/year, but decreasing the PSAV cut-points to 0.35ng/ ml/year improved sensitivity to 78% for cancer detection in this age group.
REFERENCES
1. Pu YS, Fujimoto H, Kakizoe T, Myers R. The 18th international symposium: controversies in prostate cancer diagnosis and treatment. Jpn J Clin Oncol. 2005; 35:680–9.
2. Barry MJ. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med. 2001; 344:1373–7.
3. Djavan B, Zlotta A, Kratzik C, Remzi M, Seitz C, Schulman CC, et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology. 1999; 54:517–22.
4. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992; 267:2215–20.
5. Antenor JA, Han M, Roehl KA, Nadler RB, Catalona WJ. Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J Urol. 2004; 172:90–3.
6. Ito K, Yamamoto T, Ohi M, Kubota Y, Fukabori Y, Kurokawa K, et al. Usefulness of prostate-specific antigen velocity in screening for prostate cancer. Int J Urol. 2002; 9:316–21.
7. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol. 1989; 141:1076–83.
8. Song K, Song C, Ahn H. Continuing trends of the clinical parameter migration in patients with prostate cancer in Korea. Korean J Urol. 2007; 48:574–8.
9. Anderson JR, Strickland D, Corbin D, Byrnes JA, Zweiback E. Age-specific reference ranges for serum prostate-specific antigen. Urology. 1995; 46:54–7.
10. Connolly D, Black A, Murray LJ, Napolitano G, Gavin A, Keane PF. Methods of calculating prostate-specific antigen velocity. Eur Urol. 2007; 52:1044–50.
11. Moul JW, Sun L, Hotaling JM, Fitzsimons NJ, Polascik TJ, Robertson CN, et al. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol. 2007; 177:499–504.
12. Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer. 2006; 106:320–8.
13. Ciatto S, Bonardi R, Lombardi C, Zappa M, Gervasi G, Cappelli G. Analysis of PSA velocity in 1666 healthy subjects undergoing total PSA determination at two consecutive screening rounds. Int J Biol Markers. 2002; 17:79–83.
14. Schroder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH. Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol. 2006; 49:460–5.
15. Manseck A, Pilarsky C, Froschermaier S, Menschikowski M, Wirth MP. Diagnostic significance of prostate-specific antigen velocity at intermediate PSA serum levels in relation to the standard deviation of different test systems. Urol Int. 1998; 60:25–7.
16. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ＜ or =4.0 ng per milliliter. N Engl J Med. 2004; 350:2239–46.
Table 1.
Demographics, PSA level, and PSAV in the ＜60 year-old group and the ≥60 year-old group
Table 2.
The sensitivity and specificity of PSAV in the ＜60 year-old group and the ≥60 year-old group at different PSAV thresholds
Table 3.
The performance of PSAV (ng/ml/year) threshold in the ＜60 year-old group and the ≥60 year-old group
| Age (year) | Cancer group (n) | Normal control group (n) | PSAV cut-points (ng/ml/year) | Cancers detected (%) |
|---|---|---|---|---|
| ＜60 | 45 | 7,344 | ≥0.35 | 35 (77.8) |
| ≥0.75 | 25 (55.6) | |||
| ≥60 | 55 | 2,567 | ≥0.35 | 44 (80.0) |
| ≥0.75 | 24 (43.6) |
XML Download